Genera’s low false negatives
Wednesday, 15 October, 2008
Pilot clinical trials of Genera Biosystems' [ASX: GBI] new PapType HPV detection test have shown that the test gives improved detection rates of cervical cancer than the market leader test.
Currently Qiagen's Hybrid Capture 2 test (HC2) is the only FDA-approved test for cervical cancer screening.
But in Genera's latest trials, PapType outperformed the HC2 test, returning a false negative rate of seven per cent, compared to a 27 per cent false negative rate with HC2.
Genera believes the results are very encouraging, although they are not yet conclusive.
For example, all the women in the study already had an abnormal pap smear. According to Genera, trials from the general population will need to be conducted before the superiority of PapType can be confirmed.
Irregular blood pressure patterns and dementia-associated brain changes
Hypertension has long been recognised as a risk factor for cognitive decline, yet the impact of...
How an Alzheimer's-linked protein shapes long-term memories
Tau, a protein widely associated with memory loss in dementia, has been shown to be essential for...
Multiple myeloma treatment reprograms patients' own immune cells
An Australian and Victorian Government funding agreement has allowed eligible Australians with...
